Advertisement

Diffuse Lung Disease and Lung Transplant Network

Make CHEST Physician® a trusted source
  • Machine learning meets cardiopulmonary exercise testing

    Machine learning meets cardiopulmonary exercise testing

    Cardiopulmonary exercise testing (CPET) is a clinically useful modality to discriminate between cardiac, pulmonary, and musculoskeletal limitations to physical exertion. However, it is relatively underutilized due to the lack of local expertise necessary for accurate interpretation. Several studies have explored automation of CPET interpretation, the most notable of which utilized machine learning.1 Recently, Schwendinger et…


  • Fighting for fresh air: RSV’s connection to environmental pollution

    Fighting for fresh air: RSV’s connection to environmental pollution

    Poor air quality has numerous health hazards for patients with chronic lung disease. Now mounting evidence from pediatric studies suggests a concerning link between air pollution and viral infections, specifically respiratory syncytial virus (RSV). Multiple studies have shown increased incidence and severity of disease in children with exposure to air pollutants such as particulate matter…


  • CLAD prevention in lung transplant recipients: Tacrolimus vs cyclosporin

    CLAD prevention in lung transplant recipients: Tacrolimus vs cyclosporin

    Chronic lung allograft dysfunction (CLAD) remains the leading cause of morbidity and mortality in lung transplant recipients (LTRs), accounting for around 40% of deaths.1 LTRs are typically maintained on a three-drug immunosuppressive regimen—a calcineurin inhibitor, antimetabolite agent, and corticosteroid—in order to prevent rejection. Strong randomized controlled trial-generated evidence guiding the choice of immunosuppressive therapy for…



  • Updates in evidence for rituximab in interstitial lung disease

    Updates in evidence for rituximab in interstitial lung disease

    Interstitial lung diseases (ILD) are a heterogeneous group of fibro-inflammatory disorders that can be progressive despite available therapies. The cornerstones of pharmacologic therapy include immunosuppression and antifibrotics. Data on the use of rituximab, a B-lymphocyte-depleting monoclonal antibody, often utilized as rescue therapy in progressive and severe ILD, was limited until recently. The RECITAL trial reported…


  • Use of 6-minute walk distance as a clinical trial outcome in interstitial lung disease

    Use of 6-minute walk distance as a clinical trial outcome in interstitial lung disease

    Pulmonary arterial hypertension (PH) and more recently interstitial lung disease (ILD) trials use the 6-minute walk test (6MWT) as a primary outcome due to its ability to conveniently capture a patient’s functional capacity and quality of life. However, interpreting the 6MWT in complex and diverse diseases, such as ILD, presents significant challenges. A recent article…